Liver Cancer Treatment in India and UAE | Complete Patient Guide

• ELIGIBLE PATIENTS (Curative Intent):

• Solitary HCC ≤5 cm or up to 3 nodules each ≤3 cm with preserved liver function (Child-Pugh A or select Child-Pugh B) — eligible for surgical resection or ablation

• HCC within Milan criteria (single tumor ≤5 cm, or ≤3 tumors each ≤3 cm, no vascular invasion, no extrahepatic spread) — eligible for liver transplantation (living-donor or deceased-donor)

• HCC within UCSF criteria — may be considered for transplant at select high-volume centers

• Performance status ECOG 0–1 with adequate cardiopulmonary reserve for surgical candidates

• Hepatitis B/C-related HCC with controlled viral load on antiviral therapy

• ELIGIBLE PATIENTS (Locoregional / Palliative Intent):

• Intermediate-stage HCC (BCLC B): multifocal disease without vascular invasion or extrahepatic spread — eligible for TACE or Y-90 TARE

• Tumors not amenable to surgery due to location, size, or compromised hepatic reserve — eligible for RFA, microwave ablation (MWA), or cryoablation

• Advanced-stage HCC (BCLC C) with portal vein tumor thrombus or distant metastases — eligible for systemic therapy (atezolizumab + bevacizumab; sorafenib; lenvatinib; regorafenib second-line)

• Downstaging candidates: patients with intermediate/advanced HCC who may achieve Milan criteria after locoregional therapy, subsequently transitioning to transplant evaluation

• REQUIRED PRE-TREATMENT DIAGNOSTICS:

• Dynamic contrast-enhanced MRI of the liver (preferred) or 4-phase CT scan — primary HCC diagnosis per LI-RADS criteria (LI-RADS 5 = definitive HCC without biopsy)

• Serum alpha-fetoprotein (AFP), AFP-L3 fraction, and des-gamma-carboxyprothrombin (DCP/PIVKA-II)

• Liver function tests: Child-Pugh score, MELD score, albumin-bilirubin (ALBI) grade

• Indocyanine green (ICG) retention test (15-minute clearance rate) — critical for surgical resection planning

• PET-CT scan (F-18 FDG or C-11 Acetate) for extrahepatic staging and detection of poorly differentiated HCC

• Liver volumetry (CT-based) for future liver remnant (FLR) calculation prior to major hepatectomy; portal vein embolization (PVE) considered if FLR < 30–40%

• Upper GI endoscopy for variceal assessment; echocardiography (ECHO) for transplant candidates

• Hepatitis B surface antigen, anti-HCV antibody, HBV DNA, HCV RNA quantification

• Tissue biopsy (18G core needle, ultrasound-guided) for non-classic imaging appearances or when enrollment in clinical trials is planned

• CONTRAINDICATIONS / UNFAVORABLE INDICATORS:

• Decompensated cirrhosis (Child-Pugh C) with refractory ascites, hepatic encephalopathy, or recurrent variceal bleeding — generally ineligible for major resection or systemic therapy

• Diffuse bilobar HCC with extensive portal vein tumor thrombus (PVTT) involving the main portal trunk — high-risk for hepatic failure post-TACE

• Severe portal hypertension (hepatic venous pressure gradient >10 mmHg) — relative contraindication to resection

• Active uncontrolled systemic infection

• Unresolved esophageal varices at high risk of bleeding prior to initiation of bevacizumab-based therapy

• Significant renal impairment or severe cardiovascular disease precluding contrast-based imaging or systemic therapy

SURGICAL APPROACHES:

1. Hepatic Resection (Hepatectomy): The gold-standard curative treatment for patients with solitary or oligofocal HCC and well-preserved liver function. Anatomic resection (removal of a defined hepatic segment or lobe) is preferred over non-anatomic wedge resection as it encompasses the portal territories supplying the tumor, reducing intrahepatic recurrence. Major hepatectomy (≥3 Couinaud segments) requires careful preoperative volumetric assessment and ICG testing. Robotic-assisted hepatectomy (Da Vinci Xi System) offers superior 3D magnification, tremor filtration, and articulating instruments for resections near the hepatic veins and inferior vena cava — reducing blood loss, transfusion requirements, and length of stay compared to open surgery. Laparoscopic hepatectomy is offered for peripheral, anterolateral-segment tumors. Intraoperative ultrasound (IOUS) with real-time contrast enhancement guides margin assessment.

2. Liver Transplantation: The only treatment that simultaneously removes the tumor and the underlying cirrhotic liver, addressing both the malignancy and the field defect that predisposes to recurrence. Outcomes are excellent for patients within Milan criteria (5-year survival >70%). Living-donor liver transplantation (LDLT) is a strength of leading Indian centers, where large volumes of LDLT reduce waiting times significantly compared to deceased-donor programs. Immunosuppression post-transplant uses calcineurin inhibitors (tacrolimus-based protocols) with mTOR inhibitors (everolimus) introduced for their potential anti-tumor properties.

LOCOREGIONAL THERAPIES:

3. Transarterial Chemoembolization (TACE): The reference standard for intermediate-stage HCC. Conventional TACE (cTACE) delivers a mixture of lipiodol + chemotherapeutic agent (doxorubicin or cisplatin) followed by embolic particles, exploiting the HCC's exclusive arterial blood supply. Drug-eluting bead TACE (DEB-TACE) uses microspheres loaded with doxorubicin (DC Bead®) for sustained, controlled drug release with reduced systemic toxicity. Response is assessed by modified RECIST (mRECIST) at 4–6 weeks post-procedure.

4. Transarterial Radioembolization (TARE / Y-90): Administration of yttrium-90 microspheres (SIR-Spheres® or TheraSphere®) via hepatic arterial catheterization delivers targeted internal radiation to the tumor while largely sparing normal hepatic parenchyma. Particularly advantageous for tumors with portal vein tumor thrombus (PVTT) where TACE carries higher risk. Radiation segmentectomy with Y-90 can achieve ablative doses to single-segment tumors.

5. Radiofrequency Ablation (RFA) & Microwave Ablation (MWA): Percutaneous thermal ablation is preferred for HCC ≤3 cm, especially in patients with impaired liver function who cannot tolerate resection. RFA uses alternating electrical current to generate frictional heat (60–100°C), inducing coagulative necrosis with 3–5 cm ablation zones. MWA (915 MHz or 2.45 GHz systems) generates larger, more consistent ablation zones, is less susceptible to heat-sink effect from adjacent vessels, and completes ablation faster. Both are performed under real-time ultrasound or CT guidance, or via laparoscopic approach for anteriorly located tumors.

6. Stereotactic Body Radiation Therapy (SBRT): High-dose, hypofractionated external beam radiation (typically 36–54 Gy in 3–6 fractions) delivered with sub-millimeter precision using respiratory gating and image guidance (IGRT). Suitable for HCC not amenable to ablation or TACE, and increasingly used for portal vein tumor thrombus. Proton beam therapy (PBT), available at select centers, offers the dosimetric advantage of a Bragg peak — depositing maximal dose within the tumor while minimizing radiation to adjacent normal liver.

SYSTEMIC THERAPY:

7. First-Line Immunotherapy + Anti-VEGF Combination: Atezolizumab (PD-L1 checkpoint inhibitor) + bevacizumab (anti-VEGF) — the IMbrave150 regimen — is the current preferred first-line treatment for advanced, unresectable HCC, demonstrating superior overall survival and progression-free survival versus sorafenib. Durvalumab + tremelimumab (STRIDE regimen) is an alternative first-line IO-IO combination. Pembrolizumab monotherapy is an option for patients with contraindications to bevacizumab (high variceal bleeding risk).

8. First-Line Tyrosine Kinase Inhibitors (TKIs): Sorafenib (multikinase inhibitor; RAF/VEGFR/PDGFR) and lenvatinib (VEGFR1-3/FGFR1-4 inhibitor) remain standard first-line options, particularly where IO-based therapy is contraindicated. Second-line agents include regorafenib, cabozantinib, and ramucirumab (for AFP ≥400 ng/mL).

9. Adjuvant Therapy Post-Resection/Ablation: Atezolizumab + bevacizumab is being evaluated in the adjuvant setting (IMbrave050 trial). Sorafenib adjuvant therapy demonstrated limited benefit in prior trials. Antiviral therapy (tenofovir/entecavir for HBV; direct-acting antivirals for HCV) is maintained throughout treatment to prevent viral reactivation and slow cirrhosis progression.

ADVANCED BRIDGING AND DOWNSTAGING STRATEGIES:

• Portal Vein Embolization (PVE) followed by Associating Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS) for patients with insufficient future liver remnant

• Neoadjuvant TACE or ablation as a bridge to transplantation to prevent dropout on the waiting list

• Downstaging protocols (TACE ± systemic therapy) for patients outside Milan criteria, targeting transplant eligibility

PHASE 1 — PRE-ARRIVAL WORKUP (Weeks 1–3, from home country):

• Patient submits medical records (imaging, pathology reports, lab work) to GAF Healthcare's clinical coordination team

• GAF's oncology panel conducts a virtual MDT review and issues a detailed treatment recommendation within 48–72 hours

• GAF assists with e-Medical visa application for India or UAE entry visa facilitation; visa processing typically takes 3–7 business days

• Patient books flights; GAF arranges airport pickup, hospital-adjacent accommodation for the patient and one attendant

PHASE 2 — ARRIVAL & DIAGNOSTIC CONFIRMATION (Days 1–4):

• Day 1: Airport transfer, hotel check-in, hospital orientation

• Days 2–3: Repeat or supplementary imaging if required (dynamic MRI liver, PET-CT); comprehensive blood panel (AFP, PIVKA-II, LFTs, coagulation profile, viral hepatology markers, ECHO for surgical/transplant candidates); ICG test; anesthesiology and hepatology consultation

• Day 4: MDT Tumor Board convenes with patient-present consultation; final treatment plan confirmed; consent process completed

PHASE 3 — TREATMENT (Variable by modality):

For Hepatic Resection (Open or Robotic/Laparoscopic):

• Day 5: Admission to hospital; pre-operative preparation (bowel prep, antibiotic prophylaxis, DVT prophylaxis stockings and LMWH)

• Day 6: Surgery (4–8 hours); intraoperative blood salvage (Cell Saver); ICU admission post-operatively for hemodynamic monitoring

• Days 7–10: ICU/HDU stay; nasogastric tube removal Day 1–2 post-op; drain management; early enteral nutrition initiated

• Days 11–18: Step-down ward; progressive ambulation; liver function trend monitoring (bilirubin, INR, albumin); drain removal; staple/suture removal

• Day 18–21: Discharge planning; oncology follow-up appointment scheduled

For TACE / Y-90 TARE:

• Day 5: Admission; pre-procedure hydration and antiemetic prophylaxis

• Day 6: Procedure under conscious sedation or general anesthesia (1–2 hours); femoral or radial artery access; superselective catheterization under fluoroscopic and cone-beam CT guidance

• Days 7–8: Post-embolization syndrome management (fever, pain, nausea — expected and self-limiting); IV analgesia, antiemetics; liver function and renal function monitoring

• Day 9–10: Discharge; outpatient review scheduled for Week 6 mRECIST response assessment

For Percutaneous Ablation (RFA/MWA):

• Day 5: Admission; NPO from midnight

• Day 6: Ablation procedure under IV sedation or general anesthesia (30–90 minutes); ultrasound or CT guidance; immediate post-procedural contrast CT to confirm ablation margin adequacy

• Day 7–8: Observation; pain management; liver enzyme monitoring (transient ALT/AST elevation expected)

• Day 8–9: Discharge

PHASE 4 — IN-COUNTRY RECOVERY & SURVEILLANCE (Weeks 3–8):

• Surgical patients rest at the arranged accommodation with daily nurse home-visits or outpatient clinic check-ups (wound care, drain site inspection, LFT trending)

• Week 4–5 post-resection: Surgical site fully healed; sutures/staples removed; patient can ambulate independently; light diet tolerated

• Week 6: First post-treatment imaging (dynamic MRI or CT) to assess treatment response (mRECIST for TACE; modified ablation zone assessment for RFA/MWA)

• Week 6–8: Oncology review; systemic therapy initiation discussed if applicable; fit-to-fly assessment by treating surgeon/hepatologist

• Comprehensive discharge summary, imaging CDs, pathology reports, and follow-up protocol provided to patient by GAF Healthcare coordinator

PHASE 5 — RETURN HOME & LONG-TERM FOLLOW-UP:

• Surveillance imaging every 3 months for first 2 years (dynamic MRI or 4-phase CT), then every 6 months — per AASLD/EASL guidelines

• AFP and PIVKA-II monitoring at each follow-up

• GAF Healthcare maintains telemedicine liaison with the treating team for ongoing remote consultation and report review